Featured Video
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
- MMN
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany.
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
- GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
- MMN
Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology.
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
- CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Back to Top